The US pharma industry saw a rise of 7.5% in overall deal activity during April 2019, when compared with the last 12-month average, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
A total of 86 deals worth $5.63bn were announced in April 2019, compared to the 12-month average of 80 deals.
Venture financing was the leading category in the month in terms of volume with 58 deals which accounted for 67.4% of all deals.
In second place was M&A with 20 deals, followed by private equity with eight transactions, respectively accounting for 23.3% and 9.3% of overall deal activity in the country’s pharma industry during the month.
In terms of value of deals, M&A was the leading deal category in the US pharma industry with total deals worth $3.33bn, while private equity and venture financing deals totalled $1.24bn and $1.05bn, respectively.
US pharma industry deals in April 2019: Top deals
The top five pharma industry deals accounted for 76.1% of the overall value during April 2019.
The combined value of the top five pharma industry deals stood at $4.28bn, against the overall value of $5.63bn recorded for the month. The top announced US pharma industry deal tracked by GlobalData in April 2019 was Novartis ‘ $1.58bn acquisition of IFM Tre .
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.